Indications for selected target species: Treatment of infections caused by marbrofloxacin-susceptible strains of microorganisms.
• infections of the skin and soft tissues (dysfunction of skin folds, impetigo, folliculitis, furunculosis, cellulitis)
• urinary tract infections, whether or not associated with prostatitis or epididymitis
• respiratory tract infections.
Boflox 20 mg flavored tablets for dogs
QUALITATIVE AND QUANTITATIVE COMPOSITION:
Each tablet contains:
Active substance:
Marbofloxacin 20 mg
PHARMACEUTICAL FORM:
Tablet. Longitudinal beige tablets with brown spots with a dividing line on both sides. The tablets can be divided in half.
DETAILED CLINICAL DATA
Target species of animals:
dogs
Indications for selected target animal species:
Treatment of infections caused by marbrofloxacin-susceptible strains of microorganisms.
• infections of the skin and soft tissues (dysfunction of skin folds, impetigo, folliculitis, furunculosis, cellulitis)
• urinary tract infections, whether or not associated with prostatitis or epididymitis
• respiratory tract infections.
Contraindications:
Do not use marbofloxacin in dogs less than 12 months old, and in very large breeds with a longer growth period, such as German, Briard, Bernese Mountain Dog, Bouvier and Mastiff, do not use in dogs under 18 months of age.
Do not use in cases of hypersensitivity to fluoroquinolones or any of the product’s excipients.
Do not use quinolone resistance because there is (almost) complete cross-resistance to quinolones and other fluoroquinolones.
The drug is not suitable for treating infections caused by strictly anaerobic bacteria, yeast, or fungi.
Do not use the drug on cats. For this type of treatment, 20 mg tablets with a dividing line are available.
Special warnings for each target animal species:
Low pH urine can inhibit the action of marbofloxacin.
Special precautions for use:
Special precautions for use in animals:
It has been found that fluoroquinolones cause damage to articular cartilage in growing dogs and therefore attention should be paid to dosage, especially with the use of the drug in young animals.
The neurological side effects of fluoroquinolones are also known. Use with caution in dogs with known epilepsy.
Fluoroquinolones should be reserved for the treatment of diseases that have responded poorly, or that can be expected to respond poorly to treatment with other classes of antibacterial agents. Whenever possible, fluoroquinolone therapy should be based on the results of susceptibility tests. Using a product against the ChPLW recommendations may increase the incidence of fluoroquinolone resistant bacteria and reduce the effectiveness of treatment with other quinolones due to possible cross-resistance.
While using the drug, official and local antibiotic policy guidelines should be followed.
Special precautions to be taken by the person in charge of the veterinary medicinal product for animals:
people with known hypersensitivity to (fluoride) quinolones should avoid contact with the veterinary medicinal product.
If accidentally swallowed, seek medical advice immediately and show the package leaflet or label to the doctor in charge. Wash your hands after use.
Adverse reactions (frequency and severity):
